Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Perampanel Fine Granules vs Tablet in Healthy Japanese Subjects
NCT03399734Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of perampanel in epilepsy (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum observed concentration and Area under the concentration-time curve from zero time to 168 hours. Started Dec 2017; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03399734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399734.